The Potential for Misuse and Abuse of Medications in ADHD: A Review

References

• . American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing: 2013
   Google Scholar
• . Center for Medicare and Medicaid Services. Drug Diversion in the Medicaid Program: State Strategies for Reducing Prescription Drug Diversion in Medicaid. Baltimore, MD: United States Department of Health and Human Services; 2012. http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/MedicaidIntegrityProgram/downloads/drugdiversion.pdf. Accessed August 26, 2014
   Google Scholar
• . Bloom B, Jones LI, Freeman G. (2013). Summary Health Statistics for U.S. Children: National Health Interview Survey, 2012. National Center for Health Statistics. Vital Health Stat 10(258); 2013
   Google Scholar
• . Kessler RC, Adler L, Barkley R, . The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–723
   PubMed Web of Science ®Google Scholar
• . Fayyad J, De Graaf R, Kessler R, . Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–409
   PubMed Web of Science ®Google Scholar
• . Lara C, Fayyad J, de Graaf R, . Childhood predictors of adult ADHD: results from the WHO World Mental Health (WMH) Survey Initiative. Biol Psychiatry. 2009;65(1):46–54
   PubMed Web of Science ®Google Scholar
• . Biederman J, Petty CR, Clarke A, Lomedico A, Faraone SV. Predictors of persistent ADHD: an 11-year follow-up study. J Psychiatr Res. 2011;45(2):150–155
   PubMed Web of Science ®Google Scholar
• . Kessler RC, Adler LA, Barkley R, . Patterns and predictors of ADHD persistence into adulthood: results from the National Comorbidity Survey Replication. Biol Psychiatry. 2005;57(11):1442–1451
   PubMed Web of Science ®Google Scholar
• . Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national survey results on drug use, 1975–2011: vol II, college students and adults ages 19–50. Ann Arbor: Institute for Social Research, The University of Michigan; 2012. http://www.monitoringthefuture.org/pubs/monographs/mtf-vol2_2011.pdf. Accessed August 26, 2014
   Google Scholar
• . Fuermaier AB, Tucha L, Koerts J, Mueller AK, Lange KW, Tucha O. Measurement of stigmatization towards adults with attention deficit hyperactivity disorder. PLoS One. 2012;7(12):e51755
   PubMed Web of Science ®Google Scholar
• . Cascade E, Kalali AH. Weisler RH, Lenderts S. Seasonality and the changing adult/child prescription ratios in ADHD therapy. Psychiatry (Edgmont). 2008;5(1):23–25
   PubMedGoogle Scholar
• . Suhr J, Hammers D, Dobbins-Buckland K, Zimak E, Hughes C. The relationship of malingering test failure to self-reported symptoms and neuropsychological findings in adults referred for ADHD evaluation. Arch Clin Neuropsychol. 2008;23(5):521–530
   PubMed Web of Science ®Google Scholar
• . Musso MW, Gouvier WD. “Why is this so hard?” A review of detection of malingered ADHD in college students. J Attention Discord. 2014;18(3):186–201
   PubMed Web of Science ®Google Scholar
• . Sullivan BK, May K, Galbally L. Symptom exaggeration by college adults in attention-deficit hyperactivity disorder and learning disorder assessments. Appl Neuropsychol. 2007;14(3):189–207
   PubMed Web of Science ®Google Scholar
• . Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69(12):e145–e157
   PubMed Web of Science ®Google Scholar
• . Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 3rd ed. New York, NY: Cambridge University Press; 2008
   Google Scholar
• . Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51(4):356–367
   PubMed Web of Science ®Google Scholar
• . Arnsten AF, Li BM. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry. 2005;57(11):1377–1384
   PubMed Web of Science ®Google Scholar
• . Arnsten AFT. Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011;69(12):e89–e99
   PubMed Web of Science ®Google Scholar
• . Murnane KS, Howell LL. Neuroimaging and drug taking in primates. Psychopharmacology (Berl). 2011;216(2):153–171
   PubMed Web of Science ®Google Scholar
• . Whitelaw RB, Markou A, Robbins TW, Everitt BJ. Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behaviour under a second-order schedule of reinforcement. Psychopharmacology (Berl). 1996;127(3):213–224
   PubMed Web of Science ®Google Scholar
• . Hutcheson DM, Everitt BJ. The effects of selective orbitofrontal cortex lesions on the acquisition and performance of cue-controlled cocaine seeking in rats. Ann N Y Acad Sci. 2003;1003:410–411
   PubMed Web of Science ®Google Scholar
• . Ito R, Robbins TW, Everitt BJ. Differential control over cocaine seeking behavior by nucleus accumbens core and shell. Nat NeuroSci. 2004;7(4):389–397
   PubMed Web of Science ®Google Scholar
• . Ito R, Dalley JW, Howes SR, Robbins TW, Everitt BJ. Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. J NeuroSci. 2000;20(19):7489–7495
   PubMed Web of Science ®Google Scholar
• . Rowlett JK, Platt DM, Yao WD, Spealman RD. Modulation of heroin and cocaine self-administration by dopamine D1- and D2-like receptor agonists in rhesus monkeys. J Pharmacol Exp Ther. 2007;321(3):1135–1143
   PubMed Web of Science ®Google Scholar
• . Economidou D, Dalley JW, Everitt BJ. Selective norepinephrine reuptake inhibition by atomoxetine prevents cue-induced heroin and cocaine seeking. Biol Psychiatry. 2011;69(3):266–274
   PubMed Web of Science ®Google Scholar
• . Bymaster FP, Katner JS, Nelson DL, . Atomoxetine increases extracellular levels of norepinephrine and dopamine in the prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711
   PubMed Web of Science ®Google Scholar
• . Gamo NJ, Wang M, Arnsten AFT. Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry. 2010;49(10):1011–1023
   PubMed Web of Science ®Google Scholar
• . Heil SH, Holmes HW, Bickel WK, . Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67(2):149–156
   PubMed Web of Science ®Google Scholar
• . Kawaura K, Karasawa J, Chaki S, Hikichi H. Stimulation of postsynapse adrenergic α2a receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder. Behav Brain Res. 2014;270:349–356
   PubMed Web of Science ®Google Scholar
• . Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend. 2008;95(1–2):140–146
   PubMed Web of Science ®Google Scholar
• . Upadhyaya HP, Kroutil LA, Deas D, Durell TM, Van Brunt DL, Novak SP. Stimulant formulation and motivation for nonmedical use of prescription attention-deficit/hyperactivity disorder medications in a college-aged population. Am J Addict. 2010;19(6):569–577
   PubMed Web of Science ®Google Scholar
• . McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse. 2004;39(7):1095–1116
   PubMed Web of Science ®Google Scholar
• . Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45(4):408–414
   PubMed Web of Science ®Google Scholar
• . Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57(11):1215–1220
   PubMed Web of Science ®Google Scholar
• . Upadhyaya HP. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry. 2007;68( Suppl 11):23–30
   PubMed Web of Science ®Google Scholar
• . Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis. 1997;185(8):475–482
   PubMed Web of Science ®Google Scholar
• . Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ. 2001;165(8):1039–1044
   PubMed Web of Science ®Google Scholar
• . Poulin C. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction. 2007;102(5):740–751
   PubMed Web of Science ®Google Scholar
• . Upadhyaya HP, Rose K, Wang W, . Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol. 2005;15(5):799–809
   PubMed Web of Science ®Google Scholar
• . Biederman J, Faraone SV, Mick E, . High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study. Am J Psychiatry. 1995;152(3):431–435
   PubMed Web of Science ®Google Scholar
• . Biederman J, Wilens T, Mick E, . Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997;36(1):21–29
   PubMed Web of Science ®Google Scholar
• . Molina BSG, Pelham WE Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol. 2003;112(3):497–507
   PubMed Web of Science ®Google Scholar
• . Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ. 2003;168(6):715–722
   PubMed Web of Science ®Google Scholar
• . Aldridge AP, Kroutil LA, Cowell AJ, Reeves DB, Van Brunt DL. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder. Pharmacoeconomics. 2011;29(7):621–635
   PubMed Web of Science ®Google Scholar
• . Bredeloux P, Dubuc I, Costentin J. Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br J Pharmacol. 2007;150(6):711–719
   PubMed Web of Science ®Google Scholar
• . Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem. 2010;114(1):259–270
   PubMed Web of Science ®Google Scholar
• . Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68(5):2032–2037
   PubMed Web of Science ®Google Scholar
• . Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry. 2003;64(2):110–111
   PubMed Web of Science ®Google Scholar
• . Volkow ND, Wang GJ, Fischman MW, . Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386(6627):827–830
   PubMed Web of Science ®Google Scholar
• . Kahlig KM, Binda F, Khoshbouei H, . Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A. 2005;102(9):3495–3500
   PubMed Web of Science ®Google Scholar
• . Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry. 2003;160(11):1909–1918
   PubMed Web of Science ®Google Scholar
• . Wetzell BB, Muller MM, Cobuzzi JL, Hurwitz ZE, DeCicco-Skinner K, Riley AL. Effect of age on methylphenidate-induced conditioned taste avoidance and related BDNF/TrkB signaling in the insular cortex of the rat. Psychopharmacology (Berl). 2014;231(8):1493–1501
   PubMed Web of Science ®Google Scholar
• . Andersen SL, Arvanitogiannis A, Pliakas AM, LeBlanc C, Carlezon WA Jr. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat NeuroSci. 2002;5(1):13–14
   PubMed Web of Science ®Google Scholar
• . Carlezon WA Jr, Mague SD, Andersen SL. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry. 2003;54(12):1330–1337
   PubMed Web of Science ®Google Scholar
• . Brandon CL, Marinelli M, White FJ. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biol Psychiatry. 2003;54(12):1338–1344
   PubMed Web of Science ®Google Scholar
• . Schenk S, Izenwasser S. Pretreatment with methylphenidate sensitizes rats to the reinforcing effects of cocaine. Pharmacol Biochem Behav. 2002;72(3):651–657
   PubMed Web of Science ®Google Scholar
• . Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology (Berl). 2007;191(4):867–877
   PubMed Web of Science ®Google Scholar
• . Doremus-Fitzwater TL, Varlinskaya EI, Spear LP. Motivational systems in adolescence: possible implications for age differences in substance abuse and other risk-taking behaviors. Brain Cogn. 2010;72(1):114–123
   PubMed Web of Science ®Google Scholar
• . Bogle KE, Smith BH. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev. 2009;2(2):157–176
   PubMedGoogle Scholar
• . Dupont RL, Coleman JJ, Bucher RH, Wilford BB. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict. 2008;17(3):167–171
   PubMed Web of Science ®Google Scholar
• . Barrett SP, Darredeau C, Bordy LE, Pihl RO. Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry. 2005;50(8):457–461
   PubMed Web of Science ®Google Scholar
• . Teter CJ, McCabe SE, Boyd CJ, Guthrie SK. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy. 2003;23(5):609–617
   PubMed Web of Science ®Google Scholar
• . Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy. 2006;26(10):1501–1510
   PubMed Web of Science ®Google Scholar
• . Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE, Miech RA. Monitoring the future: national survey results on drug use, 1975–2013: volume I, secondary school students. Ann Arbor: Institute for Social Research, The University of Michigan; 2014. http://www.monitoringthefuture.org/pubs/monographs/mtf-vol1_2012.pdf. Accessed August 26, 2014
   Google Scholar
• . Darredeau C, Barrett SP, Jardin B, Pihl RO. Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol. 2007;22(8):529–536
   PubMed Web of Science ®Google Scholar
• . Wilens TE, Adler LA, Adams J, . Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21–31
   PubMed Web of Science ®Google Scholar
• . Arias AJ, Gelernter J, Chan G, . Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav. 2008;33(9):1199–1207
   PubMed Web of Science ®Google Scholar
• . Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31(3):328–341
   PubMed Web of Science ®Google Scholar
• . Wilens TE, Martelon M, Joshi G, . Does ADHD predict substance use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry. 2011;50(6):543–553
   PubMed Web of Science ®Google Scholar
• . Wilens TE, Morrison NR. Substance-use disorders in adolescents and adults with ADHD: focus on treatment. Neuropsychiatry (London). 2012;2(4):301–312
   PubMedGoogle Scholar
• . Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatry. 2003;64( Suppl 11):14–18
   PubMed Web of Science ®Google Scholar
• . Kollins SH. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict. 2007;16( Suppl 1): 35–42; quiz 43–44
   PubMed Web of Science ®Google Scholar
• . Biederman J, Wilens T, Mick E, Spencer T, Faraone S. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999;104(2):e20
   PubMed Web of Science ®Google Scholar
• . Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol. 2005;15(5):764–776
   PubMed Web of Science ®Google Scholar
• . Wilens TE, Adamson J, Monuteaux MC, . Impact of prior stimulant treatment for attention-deficit hyperactivity disorder in the subsequent risk for cigarette smoking, alcohol, and drug use disorders in adolescent girls. Arch Pediatr Adolesc Med. 2008;162(10):916–921
   PubMed Web of Science ®Google Scholar
• . Mannuzza S, Klein RG, Truong NL, . Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 2008;165(5):604–609
   PubMed Web of Science ®Google Scholar
• . Kollins SH, English J, Robinson R, Hallyburton M, Chrisman AK. Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology. 2009;204(1):73–83
   PubMed Web of Science ®Google Scholar
• . Merkel RL Jr, Kuchibhatla A. Safety of stimulant treatment in attention deficit hyperactivity disorder: part 1. Expert Opin Drug Saf. 2009;8(6):655–668
   PubMed Web of Science ®Google Scholar
• . Parasrampuria DA, Schoedel KA, Schuller R, . Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol. 2007;27(5):459–467
   PubMed Web of Science ®Google Scholar
• . Spencer TJ, Biederman J, Ciccone PE, . PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006;163(3):387–395
   PubMed Web of Science ®Google Scholar
• . Berman SM, Kuczenski R, McCracken JT, London ED. Potential adverse effects of amphetamine treatment on brain and behavior: a review [published correction appears in Mol Psychiatry. 2010;15(11):1121]. Mol Psychiatry. 2009;14(2):123–142
   PubMed Web of Science ®Google Scholar
• . Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23(4):419–427
   PubMed Web of Science ®Google Scholar
• . Ermer JC, Dennis K, Haffey MB, . Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Clin Drug Investig. 2011;31(6):357–370
   PubMed Web of Science ®Google Scholar
• . Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410–418
   PubMed Web of Science ®Google Scholar
• . Cortese S, Holtmann M, Banaschewski T, ; European ADHD Guidelines Group. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227–246
   PubMed Web of Science ®Google Scholar
• . Intuniv [package insert]. Wayne, PA: Shire Inc; 2011
   Google Scholar
• . Kapvay [package insert]. Florham Park, NJ: Shionogi Pharma Inc; 2010
   Google Scholar
• . Ma CL, Qi XL, Peng JY, Li BM. Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha 2-adrenoceptors in monkeys. Neuroreport. 2003;14(7):1013–1016
   PubMed Web of Science ®Google Scholar
• . Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223–228
   PubMed Web of Science ®Google Scholar
• . Fox HC, Seo D, Tuit K, . Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings. J Psychopharmacol. 2012;26(7):958–972
   PubMed Web of Science ®Google Scholar
• . Fox HC, Morgan PT, Sinha R. Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals. Neuropsychopharmacology. 2014;39(6):1527–1537
   PubMed Web of Science ®Google Scholar
• . Kim S, Bobeica I, Gamo NJ, Arnsten AF, Lee D. Effects of α-2A adrenergic receptor agonist on time and risk preference in primates. Psychopharmacology (Berl). 2012;219(2):363–375
   PubMed Web of Science ®Google Scholar
• . Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology. 2013;64:452–463
   PubMed Web of Science ®Google Scholar
• . Gowing L, Farrell MF, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2014;3:CD002024
   PubMed Web of Science ®Google Scholar
• . Dennison SJ. Clonidine abuse among opiate addicts. Psychiatr Q. 2001;72(2):191–195
   PubMed Web of Science ®Google Scholar
• . Conway T, Balson A. Concomitant abuse of clonidine and heroin. South Med J. 1993;86(8):954–956
   PubMed Web of Science ®Google Scholar
• . Dy EC, Yates WR. Atypical drug abuse: a case report involving clonidine. Am Fam Physician. 1996;54(3):1035–1038
   PubMed Web of Science ®Google Scholar
• . Schaut J, Schnoll SH. Four cases of clonidine abuse. Am J Psychiatry. 1983;140(12):1625–1627
   PubMed Web of Science ®Google Scholar
• . Anderson F, Paluzzi P, Lee J, Huggins G, Svikis D. Illicit use of clonidine in opiate-abusing pregnant women. Obstet Gynecol. 1997;90(5):790–794
   PubMed Web of Science ®Google Scholar
• . Schindler EAD, Tirado-Morales DJ, Kushon D. Clonidine abuse in a methadone-maintained, clonazepam-abusing patient. J Addict Med. 2013;7(3):218–219
   PubMed Web of Science ®Google Scholar
• . Bender TS, Abdel-Rahman AA. Differential central NOS-NO signaling underlies clonidine exacerbation of ethanol-evoked behavioral impairment. Alcohol Clin Exp Res. 2010;34(3):555–566
   PubMed Web of Science ®Google Scholar
• . Yoon MH, Choi JI. Pharmacologic interaction between cannabinoid and either clonidine or neostigmine in the rat formalin test. Anesthesiology. 2003;99(3):701–707
   PubMed Web of Science ®Google Scholar
• . Sharma A, Newton W. Clonidine as a drug of abuse. J Am Board Fam Pract. 1995;8(2):136–138
   PubMedGoogle Scholar
• . Gahr M, Freudenmann RW, Eller J, Schönfeldt-Lecuona C. Abuse liability of centrally acting non-opioid analgesics and muscle relaxants – a brief update based on a comparison of pharmacovigilance data and evidence from the literature. Int J Neuropsychopharmacol. 2014;17(6):957–959
   PubMed Web of Science ®Google Scholar
• . Stahl SM. Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. J Clin Psychiatry. 2003;64(3):230–231
   PubMed Web of Science ®Google Scholar
• . Stahl SM. Neurotransmission of cognition, part 1, dopamine is a hitch-hiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry. 2003;64(1):4–5
   PubMed Web of Science ®Google Scholar
• . Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64(2):205–222
   PubMed Web of Science ®Google Scholar
• . Upadhyaya HP, Desaiah D, Schuh KJ, . A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2013;226(2):189–200
   PubMed Web of Science ®Google Scholar
• . Lile JA, Stoops WW, Durell TM, Glaser PEA, Rush CR. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol. 2006;14(2):136–147
   PubMed Web of Science ®Google Scholar
• . Fitzgerald PJ. Elevated norepinephrine may be a unifying etiological factor in the abuse of a broad range of substances: alcohol, nicotine, marijuana, heroin, cocaine, and caffeine. Substance Abuse. 2013;7:171–183
   PubMedGoogle Scholar
• . Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 1990;523(1):134–138
   PubMed Web of Science ®Google Scholar
• . Economidou D, Pelloux Y, Robbins TW, Dalley JW, Everitt BJ. High impulsivity predicts relapse to cocaine-seeking after punishment-induced abstinence. Biol Psychiatry. 2009;65(10):851–856
   PubMed Web of Science ®Google Scholar
• . Gasior M, Bergman J, Kallman MJ, Paronis CA. Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology. 2005;30(4):758–764
   PubMed Web of Science ®Google Scholar
• . Wee S, Woolverton WL. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend. 2004;75(3):271–276
   PubMed Web of Science ®Google Scholar
• . Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010;88(1):69–78
   PubMed Web of Science ®Google Scholar
• . Wernicke JF, Adler L, Spencer T, . Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004;24(1):30–35
   PubMed Web of Science ®Google Scholar
• . Substance Abuse and Mental Health Services Administration. Treatment for Stimulant Use Disorders. Center for Substance Abuse Treatment, US Department of Health and Human Services: Rockville, MD; 1999
   Google Scholar
• . Carlson GA, Kelly KL. Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol. 2003;13(2):137–142
   PubMed Web of Science ®Google Scholar
• . Strattera [package insert]. Indianpolis, IN: Eli Lilly and Company; 2014
   Google Scholar
• . McCabe SE, Teter CJ, Boyd CJ, Guthrie SK. Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. J Adolescent Health. 2004;35(6):501–504
   PubMed Web of Science ®Google Scholar
• . McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey [published corrections appears in Addiction. 2005;100(4):573]. Addiction. 2005;100(1):96–106
   PubMed Web of Science ®Google Scholar
• . McCabe SE, Boyd CJ, Teter CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health. 2006;54(5):269–278
   PubMed Web of Science ®Google Scholar
• . McCabe SE, Teter CJ, Boyd CJ. Medicaluse, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs. 2006;38(1):43–56
   PubMed Web of Science ®Google Scholar
• . Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health. 2005;53(6):253–262
   PubMed Web of Science ®Google Scholar
• . Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use, 1975–2012: volume 2, college students and adults ages 19–50. Ann Arbor: Institute for Social Research, The University of Michigan; 2014
   Google Scholar
• . Rabiner DL. Stimulant prescription cautions: addressing misuse, diversion, and malingering. Curr Psychiatry Rep. 2013;15(7):375
   PubMed Web of Science ®Google Scholar
• . Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med. 2008;10(5):111
   PubMedGoogle Scholar
• . Harstad E, Levy S; Committee on Substance Abuse. Attention-deficit/hyperactivity disorder and substance abuse. Pediatrics. 2014;134(1):e293–e301
   PubMed Web of Science ®Google Scholar
• . Mao AR, Babcock T, Brams M. ADHD in adults: current treatment trends with consideration of abuse potential of medications. J Psychiatr Pract. 2011;17(4):241–250
   PubMed Web of Science ®Google Scholar
• . Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. The misuse and diversion of prescribed ADHD medications by college students. J Atten Disord. 2009;13(2): 144–153
   PubMed Web of Science ®Google Scholar
• . Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. Motives and perceived consequences of nonmedical ADHD medication use by college students: are students treating themselves for attention problems? J Attent Disord. 2009;13(3): 259–270
   PubMed Web of Science ®Google Scholar
• . Sclar DA, Robison LM, Castillo LV, Bowen KA, Schmidt JM, Oganov AM. Attention deficit/hyperactivity disorder among adults in the United States: trend in diagnosis and use of pharmacotherapy. Pharmaceut Med. 2012;26(2):97–101
   Google Scholar
• . Zuvekas SH, Vitiello B. Stimulant medication use among U.S. children: a 12-year perspective. Am J Psychiatry. 2012;169(2):160–166
   PubMed Web of Science ®Google Scholar
• . Jasinski LJ, Harp JP, Berry DTR, Shandera-Ochsner AL, Mason LH, Ranseen JD. Using symptom validity tests to detect malingered ADHD in college students. Clin Neuropsychol. 2011;25(8):1415–1428
   PubMed Web of Science ®Google Scholar
• . Novak SP, Kroutil LA, Williams RL, Van Brunt DL. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy. 2007;2:32
   PubMed Web of Science ®Google Scholar
• . Sansone RA, Sansone LA. Faking attention deficit hyperactivity disorder. Innov Clin NeuroSci. 2011;8(8):10–13
   Google Scholar
• . Quinn CA. Detection of malingering in assessment of adult ADHD. Arch Clin Neuropsychol. 2003;18(4):379–395
   PubMed Web of Science ®Google Scholar
• . Harrison AG, Edwards MJ, Parker KCH. Identifying students faking ADHD: preliminary findings and strategies for detection. Arch Clin Neuropsychol. 2007;22(5):577–588
   PubMed Web of Science ®Google Scholar
• . Jachimowicz G, Geiselman RE. Comparison of ease of falsification of attention deficit hyperactivity disorder diagnosis using standard behavioral rating scales. Cognitive Science Online. 2004;2:6–20. http://cogsci-online.ucsd.edu/. Accessed August 26, 2014
   Google Scholar
• . Lee Booksh R, Pella RD, Singh AN, Drew Gouvier W. Ability of college students to simulate ADHD on objective measures of attention. J Atten Disord. 2010;13(4):325–338
   PubMed Web of Science ®Google Scholar
• . Tucha L, Sontag TA, Walitza S, Lange KW. Detection of malingered attention deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2009;1(1):47–53
   PubMedGoogle Scholar
• . Sollman MJ, Ranseen JD, Berry DTR. Detection of feigned ADHD in college students. Psychol Assess. 2010;22(2):325–335
   PubMed Web of Science ®Google Scholar
• . Harp JP, Jasinski LJ, Shandera-Ochsner AL, Mason LH, Berry DTR. Detection of malingered ADHD using the MMPI-2-RF. Psychol Inj Law. 2011;4(1):32–43
   Google Scholar
• . Young CJ, Gross AM. Detection of response bias and noncredible performance in adult attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol. 2011;26(3):165–175
   PubMed Web of Science ®Google Scholar
• . Marshall P, Schroeder R, O'Brien J, . Effectiveness of symptom validity measures in identifying cognitive and behavioral symptom exaggeration in adult attention deficit hyperactivity disorder. Clin Neuropsychol. 2010;24(7):1204–1237
   PubMed Web of Science ®Google Scholar
• . Suhr JA, Sullivan BK, Rodriguez JL. The relationship of noncredible performance to continuous performance test scores in adults referred for attention-deficit/hyperactivity disorder evaluation. Arch Clin Neuropsychol. 2011;26(1):1–7
   PubMed Web of Science ®Google Scholar
• . Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, US Department of Health and Human Services; Rockville, MD; 2006
   Google Scholar
• . Sepúlveda DR, Thomas LM, McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students. J Pharm Pract. 2011;24(6):551–560
   PubMedGoogle Scholar
• . Cohen AL, Jhung MA, Budnitz DS. Stimulant medications and attention deficit-hyperactivity disorder. N Engl J Med. 2006;354(21):2294–2295
   PubMed Web of Science ®Google Scholar
• . Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN Report: Emergency Department Visits Involving Attention Deficit/Hyperactivity Disorder Stimulant Medications. Rockville, MD. http://www.samhsa.gov/data/2k13/dawn073/sr073-add-adhd-medications.htm. Accessed August 26, 2014
   Google Scholar
• . Klein-Schwartz W, McGrath J. Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry. 2003;42(3):288–294
   PubMed Web of Science ®Google Scholar
• . Merkel RL. Safety of stimulant treatment in attention deficit hyperactivity disorder: part II. Expert Opin Drug Saf. 2010;9(6):917–935
   PubMed Web of Science ®Google Scholar
• . Vetter VL, Elia J, Erickson C, ; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing [published correction appears in Circulation. 2009;120(7):e55–e59]. Circulation. 2008;117(18):2407–2423
   PubMedGoogle Scholar
• . Kaye S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007;102(8):1204–1211
   PubMed Web of Science ®Google Scholar
• . Cox S, Posner SF, Kourtis AP, Jamieson DJ. Hospitalizations with amphetamine abuse among pregnant women. Obstet Gynecol. 2008;111(2 Pt 1):341–347
   PubMed Web of Science ®Google Scholar
• . Advokat C. Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD. J Atten Disord. 2007;11(1):8–16
   PubMedGoogle Scholar
• . Bamford NS, Zhang H, Joyce JA, . Repeated exposure to methamphetamine causes long-lasting presynaptic corticostriatal depression that is renormalized with drug readministration. Neuron. 2008;58(1):89–103
   PubMed Web of Science ®Google Scholar
• . Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use, 1975–2010. Volume II: college students and adults ages 19–50. Ann Arbor: Institute for Social Research, The University of Michigan; 2011
   Google Scholar
• . Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood – a naturalistic long-term follow-up study. Addict Behav. 2014;39(1):325–328
   PubMed Web of Science ®Google Scholar
• . Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50(1):9–21
   PubMed Web of Science ®Google Scholar
• . Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics. 2003;111(1):97–109
   PubMed Web of Science ®Google Scholar
• . Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/ hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179–185
   PubMed Web of Science ®Google Scholar
• . Wilson JJ, Levin FR. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol. 2005;15(5):751–763
   PubMed Web of Science ®Google Scholar
• . Sweeney CT, Sembower MA, Ertischek MD, Shiffman S, Schnoll SH. Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse. J Addict Dis. 2013;32(1):1–10
   PubMed Web of Science ®Google Scholar
• . Biederman J, Monuteaux MC, Spencer T, Wilens TE, MacPherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008;165(5):597–603
   PubMed Web of Science ®Google Scholar
• . Volkow ND, Wang GJ, Newcorn J, . Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. Neuroimage. 2007;34(3):1182–1190
   PubMed Web of Science ®Google Scholar
• . Volkow ND, Wang GJ, Newcorn J, . Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64(8):932–940
   PubMed Web of Science ®Google Scholar
• . Volkow ND, Wang GJ, Kollins SH, . Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302(10):1084–1091
   PubMed Web of Science ®Google Scholar
• . Chen LY, Strain EC, Alexandre PK, Alexander GC, Mojtabai R, Martins SS. Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. Addict Behav. 2014;39(5):829–836
   PubMed Web of Science ®Google Scholar
• . Somkuwar SS, Jordan CJ, Kantak KM, Dwoskin LP. Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions. Neuropsychopharmacology. 2013;38(13):2588–2597
   PubMed Web of Science ®Google Scholar
• . Jordan CJ, Harvey RC, Baskin BB, Dwoskin LP, Kantak KM. Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments. Drug Alcohol Depend. 2014;140:25–32
   PubMed Web of Science ®Google Scholar
• . Garnock-Jones KP, Keating GM. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs. 2010;24(1):85–88
   PubMed Web of Science ®Google Scholar
• . McCabe SE, West BT. Medical and nonmedical use of prescription stimulants: results from a national multicohort study. J Am Acad Child Adolesc Psychiatry. 2013;52(12):1272–1280
   PubMed Web of Science ®Google Scholar
• . Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006;84(2):135–143
   PubMed Web of Science ®Google Scholar
• . Cruz MP. Guanfacine extended-release tablets (Intuniv), a nonstimulant selective alpha(2 A)-adrenergic receptor agonist for attention-deficit/hyperactivity disorder. P T. 2010;35(8):448–451
   PubMedGoogle Scholar
• . Erder MH, Xie J, Signorovitch JE, . Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy. 2012;10(6):381–395
   PubMedGoogle Scholar
• . Adderall XR [package insert]. Wayne, PA: Shire Inc; 2013
   Google Scholar
• . Vyvanse [package insert]. Wayne, PA: Shire Inc; 2012
   Google Scholar
• . Concerta [package insert]. Titusville, NJ: McNeil Pediatrics; 2010
   Google Scholar
• . Focalin XR [package insert]. Gainesville, GA: Novartis; 2012
   Google Scholar
• . Lensing MB, Zainer P, Sandvik L, Opjordsmoen S. Adults with ADHD: use and misuse of stimulant medication as reported by patients and their primary care physicians. Atten Defic Hyperact Disord. 2013;5(4):369–376
   PubMedGoogle Scholar
• . Kratochvil CJ, Heiligenstein JH, Dittman R, . Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41(7):776–784
   PubMed Web of Science ®Google Scholar